92 research outputs found
Patient and practitioner satisfaction with tele-dermatology including Australia’s indigenous population: A systematic review of the literature
AbstractBackgroundAustralia’s health disparity, combined with evolving technologies, has evoked increasing interest and funding in health services that could address inequities. One such emerging service is tele-medicine.ObjectiveThe purpose of this report is to discuss and evaluate the current literature regarding patient and practitioner satisfaction with tele-medicine, and more specifically tele-dermatology.MethodsWe searched for literature relevant to tele-dermatology use among Australia’s indigenous population. We synthesized the literature in our report and identified elements of tele-dermatology not yet researched.ResultsMost significantly, all available research is currently based on descriptive studies and there is no validated tool to assess the efficacy of tele-dermatology.LimitationsNo published research currently exists on the use of tele-dermatology among Australia’s indigenous population.ConclusionA review of the literature shows that tele-dermatology is considered a valuable service, particularly to patients living in rural areas who might not otherwise have access to specialist care
Recessive dystrophic epidermolysis bullosa (RDEB) complicated by secondary hepatic amyloidosis
Editorial: Challenges of COVID-19 in dermatology patients on immunosuppression: risk, outcome, vaccination and beyond, volume II
Epidemiology of epidermolysis bullosa in the antipodes: The Australasian epidermolysis bullosa registry with a focus on Herlitz junctional epidermolysis bullosa
To present epidemiologic and clinical data from the Australasian Epidermolysis Bullosa (EB) Registry, the first orphan disease registry in Australia. Design: Observational study (cross-sectional and longitudinal). Setting: Australian private dermatology practice, inpatient ward, and outpatient clinic. Patients: Systematic case finding of patients with EB simplex, junctional EB (JEB), and dystrophic EB and data collection were performed throughout Australia and New Zealand from January 1, 2006, through December 31, 2008. Patients were consecutively enrolled in the study after clinical assessment and laboratory diagnosis. Medical records were retrospectively examined, and physicians involved in EB care were contacted to obtain patient history. A Herlitz JEB case series was prepared from registry data. Main Outcome Measures: Demographics and prognosis of patients with Herlitz JEB. Results: A total of 259 patients were enrolled in the study: 139 with EBS, 91 with dystrophic EB, 28 with JEB, and 1 with Kindler syndrome. Most enrollees were Australian citizens (n=243), with an Australian prevalence rate of 10.3 cases per million. The age range in the registry was birth to 99 years, with a mean and median age of 24.1 and 18.0 years, respectively. Ages were similar in patients with EBS and dominant dystrophic EB but were markedly lower in patients with JEB. Patients with Herlitz JEB (n=10) had the highest morbidity and mortality rates, with a mean age at death of 6.8 months. Sepsis, failure to thrive, and tracheolaryngeal complications were the leading causes of death. Conclusions: The Australasian EB registry is the first registry in Australia and New Zealand to provide original data on age, sex, ethnicity, and geographical and disease subtype distribution. The Australasian Herlitz JEB cohort witnessed a high infant mortality rate and poor prognosis overall
Meeting report: Women’s Dermatology Society Forum at the 25th World Congress of Dermatology, Singapore, 2023
Phase 2B randomized study of nemolizumab in adults with moderate-to-severe atopic dermatitis and severe pruritus
Background: Nemolizumab targets the IL-31 receptor a subunit
involved in atopic dermatitis (AD) pathogenesis.
Objective: We sought to evaluate a new dosing strategy of
nemolizumab in patients with AD.
Methods: We performed a 24-week, randomized, double-blind,
multicenter study of nemolizumab (10, 30, and 90 mg)
subcutaneous injections every 4 weeks versus placebo, with
topical corticosteroids in adults with moderate-to-severe AD,
severe pruritus, and inadequate control with topical treatment
(n 5 226). The Eczema Area and Severity Index (EASI), the
peak pruritus (PP) numeric rating scale (NRS), and the
Investigator’s Global Assessment (IGA) were assessed. Standard
safety assessments were performed.
Results: Nemolizumab improved EASI, IGA, and/or NRS-itch
scores, with the 30-mg dose being most effective.
Nemolizumab (30 mg) reduced EASI scores versus placebo at
week 24 (268.8% vs 252.1%, P 5 .016); significant
differences were observed by week 8 (P <_ .01). With significant
improvement (P 5 .028) as early as week 4, IGA 0/1 rates
were higher for 30 mg of nemolizumab versus placebo at week
16 (33.3% vs 12.3%, P 5 .008) but not week 24 because of an
increased placebo/topical corticosteroid effect (36.8% vs
21.1%, P 5 .06). PP-NRS scores were improved for 30 mg of
nemolizumab versus placebo at week 16 (268.6% vs 234.3%,
P <.0001) and week 24 (267.3% vs 235.8%, P <.0001), with a
difference by week 1 (P _4-point
decrease) were greater for 30 mg of nemolizumab versus
placebo at week 16 (P <_ .001) and week 24 (P <_ .01).
Nemolizumab was safe and well tolerated. The most common
adverse events were nasopharyngitis and upper respiratory
tract infection.
Conclusions: Nemolizumab resulted in rapid and sustained
improvements in cutaneous signs of inflammation and pruritus
in patients with AD, with maximal efficacy observed at 30 mg.
Nemolizumab had an acceptable safety profile. (J Allergy Clin
Immunol 2020;145:173-82.
Correction to: Long-term safety and efficacy of vismodegib in patients with advanced basal cell carcinoma: final update of the pivotal ERIVANCE BCC study
Following publication of the original article [1], it was reported that the legend for Fig. 1 was incomplete. The complete figure legend is:https://deepblue.lib.umich.edu/bitstream/2027.42/148648/1/12885_2019_Article_5568.pd
Perspective From the 5th International Pemphigus and Pemphigoid Foundation Scientific Conference
The 5th Scientific Conference of the International Pemphigus and Pemphigoid Foundation (IPPF), “Pemphigus and Pemphigoid: A New Era of Clinical and Translational Science” was held in Orlando, Florida, on May 15–16, 2018. Scientific sessions covered recent, ongoing, and future clinical trials in pemphigus and bullous pemphigoid, disease activity and quality of life instruments, and the IPPF Natural History Study. Furthermore, the meeting provided an opportunity to hear firsthand from patients, investigators, and industry about their experience enrolling for clinical trials
- …